Cargando…

Introduction: MHC/KIR and governance of specificity

The MHC controls specificity, to ensure that appropriate immune responses are mounted to invading pathogens whilst maintaining tolerance to the host. It encodes molecules that act as sentinels, providing a snapshot of the health of the interior and exterior of the cell for immune surveillance. To ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Kelly, Adrian, Trowsdale, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537316/
https://www.ncbi.nlm.nih.gov/pubmed/28695288
http://dx.doi.org/10.1007/s00251-017-0986-6
_version_ 1783254150437404672
author Kelly, Adrian
Trowsdale, John
author_facet Kelly, Adrian
Trowsdale, John
author_sort Kelly, Adrian
collection PubMed
description The MHC controls specificity, to ensure that appropriate immune responses are mounted to invading pathogens whilst maintaining tolerance to the host. It encodes molecules that act as sentinels, providing a snapshot of the health of the interior and exterior of the cell for immune surveillance. To maintain the ability to respond appropriately to any disease requires a delicate balance of expression and function, and many subtleties of the system have been described at the gene, individual and population level. The main players are the highly polymorphic classical MHC class I and class II molecules, as well as some non-classical loci of both types. Transporter associated with antigen processing (TAP) peptide transporters, proteasome components and Tapasin, encoded within the MHC, are also involved in selection of peptide for presentation. The plethora of mechanisms microorganisms use to subvert immune recognition, through blocking these antigen processing and presentation pathways, attests to the importance of HLA in resistance to infection. There is continued interest in MHC genetics in its own right, as well as in relation to KIR, to transplantation, infection, autoimmunity and reproduction. Also of topical interest, cancer immunotherapy through checkpoint inhibition depends on highly specific recognition of cancer peptide antigen and continued expression of HLA molecules. Here, we briefly introduce some background to the MHC/KIR axis in man. This special issue of immunogenetics expands on these topics, in humans and other model species.
format Online
Article
Text
id pubmed-5537316
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-55373162017-08-15 Introduction: MHC/KIR and governance of specificity Kelly, Adrian Trowsdale, John Immunogenetics Review The MHC controls specificity, to ensure that appropriate immune responses are mounted to invading pathogens whilst maintaining tolerance to the host. It encodes molecules that act as sentinels, providing a snapshot of the health of the interior and exterior of the cell for immune surveillance. To maintain the ability to respond appropriately to any disease requires a delicate balance of expression and function, and many subtleties of the system have been described at the gene, individual and population level. The main players are the highly polymorphic classical MHC class I and class II molecules, as well as some non-classical loci of both types. Transporter associated with antigen processing (TAP) peptide transporters, proteasome components and Tapasin, encoded within the MHC, are also involved in selection of peptide for presentation. The plethora of mechanisms microorganisms use to subvert immune recognition, through blocking these antigen processing and presentation pathways, attests to the importance of HLA in resistance to infection. There is continued interest in MHC genetics in its own right, as well as in relation to KIR, to transplantation, infection, autoimmunity and reproduction. Also of topical interest, cancer immunotherapy through checkpoint inhibition depends on highly specific recognition of cancer peptide antigen and continued expression of HLA molecules. Here, we briefly introduce some background to the MHC/KIR axis in man. This special issue of immunogenetics expands on these topics, in humans and other model species. Springer Berlin Heidelberg 2017-07-10 2017 /pmc/articles/PMC5537316/ /pubmed/28695288 http://dx.doi.org/10.1007/s00251-017-0986-6 Text en © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review
Kelly, Adrian
Trowsdale, John
Introduction: MHC/KIR and governance of specificity
title Introduction: MHC/KIR and governance of specificity
title_full Introduction: MHC/KIR and governance of specificity
title_fullStr Introduction: MHC/KIR and governance of specificity
title_full_unstemmed Introduction: MHC/KIR and governance of specificity
title_short Introduction: MHC/KIR and governance of specificity
title_sort introduction: mhc/kir and governance of specificity
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537316/
https://www.ncbi.nlm.nih.gov/pubmed/28695288
http://dx.doi.org/10.1007/s00251-017-0986-6
work_keys_str_mv AT kellyadrian introductionmhckirandgovernanceofspecificity
AT trowsdalejohn introductionmhckirandgovernanceofspecificity